Insulin-like growth factor-I and wound healing, a potential answer to non-healing wounds: A systematic review of the literature and future perspectives
| Autor: | Gregory Kouraklis, Zoe Garoufalia, Dimitrios Mantas, Argyro Papadopetraki, Elli Karatza, Anastassios Philippou, Dimitrios Vardakostas |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
integumentary system
business.industry General Neuroscience medicine.medical_treatment Growth factor MEDLINE General Medicine Articles Bioinformatics General Biochemistry Genetics and Molecular Biology Clinical trial Insulin-like growth factor In vivo Medicine Animal studies General Pharmacology Toxicology and Pharmaceutics business Wound healing Healing wounds |
| Zdroj: | Biomed Rep |
| Popis: | The induction of wound healing by insulin-like growth factor-I (IGF-I) has been demonstrated in several animal studies; however, there are disproportionately fewer studies assessing its value in humans. The aim of the present review is to provide a comprehensive summary of all the available evidence pertaining to the effects of IGF-I administration on the process of wound anaplasias, both in human tissues in vivo and in cells in vitro. A systematic search of Medline, Scopus and Google Scholar was performed for relevant studies published until May 2020. Overall, 11 studies were included. Of these, 2 studies were conducted in human subjects, whereas the rest of them were performed using in vitro models of human cell lines. All studies demonstrated a positive association between IGF-I and wound anaplasias; IGF-I promoted the migration of keratinocytes, thus playing an important role in wound epithelialization as well as enabling wound bed contraction, and it also stimulated hyaluronan synthesis. The wound healing-promoting effect of IGF-I may be a great asset in dealing with the healing of challenging wounds; thus, this type of treatment could be extremely useful in addressing patients with large burn wounds, chronic diabetic ulcers and patients with impaired wound healing. Nevertheless, the route of recombinant IGF-I administration, the recommended dosage, as well as the indications for clinical use of this growth factor remain to be determined and thus, additional clinical trials are required, with a focus on the medical use of recombinant IGF-I in wound anaplasias. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|